Loading
Quest Diagnostics' blood test for leftover cancer after surgery, with an FDA Breakthrough Device designation in stage II bowel cancer.
Haystack MRD comes from Haystack Oncology of Baltimore, which Quest Diagnostics acquired on 21 June 2023. Quest introduced it as a laboratory-developed test in late 2024. It sequences the tumour's exome to choose up to 50 variants and states that it detects 95% of cases at a tumour fraction of 0.0006% (company data on file). On 25 August 2025 the FDA granted Breakthrough Device designation for identifying MRD-positive patients with stage II colorectal cancer after curative-intent surgery who may benefit from adjuvant therapy, and New York State approved it in June 2026 for residual or recurring disease in solid tumours. The chemistry descends from Safe-SeqS, the method used in the DYNAMIC trial of ctDNA-guided adjuvant chemotherapy in stage II colon cancer.
Whole-exome sequencing of tumour tissue and a matched normal blood sample designs a personalised panel of up to 50 variants, which is tracked in plasma.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Haystack MRD" OR ABSTRACT:"Haystack MRD") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Haystack MRD, not a curated reading list.
Shares RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera and the tag test.
Shares RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera and the tag test.
Shares RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/